MedTrace Logo

Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder

NCT01119430 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-05-07

No results posted yet for this study

Summary

The purpose of this study is to examine whether the speed of the clinical antidepressant action of fluoxetine can be accelerated by administering DU125530 a full 5-HT1A antagonist.

Conditions

Interventions

DRUG

DU125530

20mg/twice a day

DRUG

Placebo

Similar pill as active comparator twice a day

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Victor Pérez, MD, PhD · Psychiatrist, Hospital de Sant Pau

  • Enric Álvarez, MD, PhD · Head of Departement, Psiquiatria, Hospital de Sant Pau

  • Dolors Puigdemont, MD · Psychiatrist, Hospital de Sant Pau

  • Josefina Pérez, MD · Psychiatrist, Hospital de Sant Pau

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01119430 on ClinicalTrials.gov